Thymosin Beta 4 Derivatives for Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for skin lesions, heart injuries, and coronary heart diseases are limited in efficacy, particularly in promoting tissue repair and preventing scarring, with native thymosin β4 showing moderate therapeutic effects.
Innovation Solution
Development of thymosin β4 derivatives, Gly-Tβ4 and Ala-Tβ4, with modified N-termini, produced through genetic engineering and chemical synthesis, which exhibit enhanced activity in tissue repair and heart function improvement compared to native Tβ4.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If native thymosin β4 is used for tissue repair, then therapeutic effect is achieved, but activity is limited and treatment duration is prolonged
Solution Approach 1:
The patent applies parameter changes by modifying the N-terminal amino acid sequence of thymosin β4 (changing Met-Asn-Gln to Gly or Ala), which alters the molecular structure and significantly enhances its biological activity, achieving faster tissue repair and heart function improvement
Solution Approach 2:
The patent applies local quality by specifically modifying only the N-terminal region of the thymosin β4 molecule while keeping the rest of the structure intact, thereby locally improving the protein's therapeutic properties without altering its fundamental function
2Reliability
If native thymosin β4 is used for wound healing, then healing is achieved, but fibrosis and scarring occur
Solution Approach 1:
The patent modifies the N-terminal parameters of thymosin β4 to create derivatives (Gly-Tβ4, Ala-Tβ4) that promote wound healing through enhanced epithelialization and angiogenesis while simultaneously reducing fibrosis and scarring compared to native Tβ4
3Productivity
If genetic engineering method is used to produce Tβ4 derivatives, then production efficiency is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the production process into distinct stages: constructing expression vectors with specific sequences (SEQ ID NO: 5 or 6), transforming host cells, inducing expression, and purifying the derivatives through chromatography, allowing each step to be optimized independently
Solution Approach 2:
The patent employs self-service by using bacterial expression systems that automatically produce the thymosin β4 derivatives when provided with the appropriate expression vectors and growth conditions, eliminating the need for complex chemical synthesis procedures
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to thymosin β4 (Tβ4) derivatives, Gly-Tβ4 and Ala-Tβ4. The present invention further relates to a pharmaceutical composition comprising the said Tβ4 derivatives. The present invention also relates to the use of said Tβ4 derivatives in manufacture of a medicament for treatment of skin lesion, heart injury, corneal lesion and/or coronary heart disease. The present invention further relates to a method of treatment for skin lesion, heart injury, corneal lesion and/or coronary heart disease by using the said Tβ4 derivatives.